TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23449426

Group type: EXPERIMENTAL
Intervention: Allopurinol 600 mg/day for 9 months
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 20941634

Group type: EXPERIMENTAL
Intervention: Bio-active glass air abrasion
Number of subjects: 38

Group type: COMPARATOR
Intervention: Alumina air abrasion
Number of subjects: 38
Study: 18840205

Group type: EXPERIMENTAL
Intervention: Walking intervention
Number of subjects: 248
Study: 16818810

Group type: COMPARATOR
Intervention: Beta-blocker therapy (control group)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Amiodarone plus beta-blocker
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 94
Study: 12507797

Group type: EXPERIMENTAL
Intervention: Mandatory drug testing (DT)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Control (C) - No mandatory drug testing
Number of subjects: 276
Study: 10688394

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2% BID
Number of subjects: 94

Group type: COMPARATOR
Intervention: Timolol 0.5% BID
Number of subjects: 94
Study: 9449474

Group type: EXPERIMENTAL
Intervention: human recombinant IFN-beta1a (3 MIU or 9 MIU subcutaneously 3x a week)
Number of subjects: 68
Study: 7993150

Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccination
Number of subjects: 12
Study: 3282670

Group type: EXPERIMENTAL
Intervention: Flunarizine (5 mg/day)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 30515995

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) - one telephone session
Number of subjects: 112

Group type: COMPARATOR
Intervention: Reminder calls (Control)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) - two sessions (one telephone and one in person)
Number of subjects: 112
Study: 28490725

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 68
Study: 26150167

Group type: EXPERIMENTAL
Intervention: Custom-fit, ultralightweight manual wheelchairs with propulsion/skills training and support calls
Number of subjects: 14

Group type: COMPARATOR
Intervention: No training, using own wheelchairs
Number of subjects: 14
Study: 23956241

Group type: EXPERIMENTAL
Intervention: Memantine (20 mg/d)
Number of subjects: 508

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 508
Study: 21649520

Group type: EXPERIMENTAL
Intervention: Individualized, water‐based herbal decoctions (Verum group)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Nonspecific presumably ineffective, water‐based herbal decoctions (Control group)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Both groups (Verum and Control)
Number of subjects: 102
Study: 17934824

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound (EUS)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Endoscopic retrograde pancreatography (ERP)
Number of subjects: 83
Study: 16507849

Group type: EXPERIMENTAL
Intervention: as-needed formoterol 4.5 microg Turbuhaler
Number of subjects: 211

Group type: COMPARATOR
Intervention: as-needed salbutamol 100 microg Turbuhaler
Number of subjects: 211
Study: 12946491

Group type: EXPERIMENTAL
Intervention: Topical methylprednisolone (80 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Topical lidocaine 5% (15 puffs)
Number of subjects: 60
Study: 15017487

Group type: EXPERIMENTAL
Intervention: Once-daily mesalamine (QD)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional dosing mesalamine (CD)
Number of subjects: 22
Study: 9925862

Group type: EXPERIMENTAL
Intervention: rHuEPO (150 IU/kg/d, 3 times a week, subcutaneously) for 2 months
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no rHuEPO)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: rHuEPO in non-CDDP chemotherapy regimens
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: rHuEPO in CDDP-containing regimens
Number of subjects: 34
Study: 8800821

Group type: COMPARATOR
Intervention: Naloxone at 10% or less of the 24 h dose of morphine (placebo controlled)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Naloxone at 20% of the 24 h dose of morphine
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Naloxone at maximum doses of 20%, 40%, and 80% of the 24 h dose of morphine
Number of subjects: 17
Study: 1386766

Group type: EXPERIMENTAL
Intervention: Ketoconazole 2% foaming gel
Number of subjects: 62

Group type: COMPARATOR
Intervention: Betamethasone dipropionate 0.05% lotion
Number of subjects: 62
Study: 6731019

Group type: EXPERIMENTAL
Intervention: Arthrography performed after reduction of the dislocation
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Surgery with exploration and suture of both the ulnar and the radial collateral ligaments (randomized half of the patients)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Leakage of the contrast medium
Number of subjects: 14
Study: 3728637

Group type: EXPERIMENTAL
Intervention: Pierce saccade test (group I initial testing)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: King-Devick saccade test (group I initial testing)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Pierce saccade test (group I retest)
Number of subjects: 63

Group type: COMPARATOR
Intervention: King-Devick saccade test (group I retest)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Pierce saccade test (group II initial testing)
Number of subjects: 63

Group type: COMPARATOR
Intervention: King-Devick saccade test (group II initial testing)
Number of subjects: 63
Study: 31326629

Group type: EXPERIMENTAL
Intervention: Cell saver blood reinfused intraoperatively
Number of subjects: 89

Group type: COMPARATOR
Intervention: Allogenic blood
Number of subjects: 89

Group type: COMPARATOR
Intervention: Visible blood loss (EBL and blood loss from drains)
Number of subjects: 89
Study: 28954455

Group type: EXPERIMENTAL
Intervention: Sibelium in combination with dibazole
Number of subjects: 136

Group type: COMPARATOR
Intervention: Sibelium only (Control)
Number of subjects: 136
Study: 25726404

Group type: EXPERIMENTAL
Intervention: Customized slide show and short videotape presentation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Modified informed consent document without videotape
Number of subjects: 70
Study: 24494330

Group type: EXPERIMENTAL
Intervention: Dysphonic voice samples
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal voice samples
Number of subjects: 40
Study: 21461638

Group type: EXPERIMENTAL
Intervention: Intranasal insulin (20 U [0.2 ml])
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (0.2 ml)
Number of subjects: 32
Study: 19232896

Group type: EXPERIMENTAL
Intervention: Bivalirudin plus eptifibatide
Number of subjects: 200

Group type: COMPARATOR
Intervention: Bivalirudin
Number of subjects: 200
Study: 16822101

Group type: EXPERIMENTAL
Intervention: Parent bibliotherapy (written materials for parents)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Standard group treatment
Number of subjects: 267

Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 267
Study: 15545047

Group type: EXPERIMENTAL
Intervention: Meat products enriched with plant sterols (1.2 g/day), potassium, calcium and magnesium (MP1)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Meat products with plant sterols (2.1 g/day), potassium, calcium and magnesium (MP2)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control meat products (no added plant sterols and minerals)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Meat products with no added plant sterols and minerals (control)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: All test periods
Number of subjects: 21
Study: 11545671

Group type: EXPERIMENTAL
Intervention: Collaborative Care (CC) - educational videotapes and pamphlets; pharmacotherapy with paroxetine; 2 psychiatrist visits and 2 telephone calls in the first 8 weeks; up to 5 telephone calls between 3 and 12 months' follow-up
Number of subjects: 115

Group type: COMPARATOR
Intervention: Usual Care (UC) - treated by primary care physician
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Collaborative Care (CC)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 115
Study: 9243340

Group type: EXPERIMENTAL
Intervention: High-structure, behaviorally-oriented (HSB) individual counseling style
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Low-structure, facilitative (LSF) individual counseling style
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Coping measures (conceptual and developmental levels of functioning, field independence, social independence)
Number of subjects: 16
Study: 8494706

Group type: EXPERIMENTAL
Intervention: MPA (100 mg tds orally)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 3480298

Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration with teflon membrane placement
Number of subjects: 37

Group type: COMPARATOR
Intervention: Conventional therapy without teflon membrane
Number of subjects: 37
Study: 29780236

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination (FDC) of fimasartan (60 mg), amlodipine (10 mg), and rosuvastatin (20 mg) administered once
Number of subjects: 60

Group type: COMPARATOR
Intervention: Co-administration of fimasartan (60 mg), amlodipine (10 mg), and rosuvastatin (20 mg) administered twice
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (FDC and co-administration)
Number of subjects: 60
Study: 25967606

Group type: EXPERIMENTAL
Intervention: Korean red ginseng (1.5-g daily)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 25529502

Group type: EXPERIMENTAL
Intervention: Diagram‐Based Restudy (DBR)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Text‐Based Restudy (TBR)
Number of subjects: 128
Study: 22562983

Group type: EXPERIMENTAL
Intervention: MTX+TCZ (tocilizumab 8 mg/kg every 4 weeks)
Number of subjects: 556

Group type: COMPARATOR
Intervention: TCZ+PBO (tocilizumab and placebo)
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: MTX+TCZ
Number of subjects: 556

Group type: COMPARATOR
Intervention: TCZ+PBO
Number of subjects: 556
Study: 21968126

Group type: EXPERIMENTAL
Intervention: rosuvastatin 20 mg daily
Number of subjects: 17802

Group type: EXPERIMENTAL
Intervention: prediction based treatment
Number of subjects: 17802

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17802
Study: 18721079

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sham Electroacupuncture (sham EA)
Number of subjects: 19
Study: 16792053

Group type: EXPERIMENTAL
Intervention: Er:YAG Laser (KEY 3, KaVo)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Ultrasonic scaler (Piezon Master 400, EMS)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Sonic scaler (Sonicflex 2003 L, KaVo)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control (Gracey Mini-five curettes, Hu Friedy)
Number of subjects: 72
Study: 12923797

Group type: EXPERIMENTAL
Intervention: Procedural audiotape
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coping audiotape
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emotional audiotape
Number of subjects: 0
Study: 10863968

Group type: EXPERIMENTAL
Intervention: High ligation of the spermatic vein
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (untreated varicocele patients)
Number of subjects: 75
Study: 9160025

Group type: EXPERIMENTAL
Intervention: One-piece PMMA IOL
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Three-piece silicone IOL
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Three-piece acrylic soft IOL
Number of subjects: 225

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 225
Study: 8370428

Group type: EXPERIMENTAL
Intervention: UK‐38,485 (600 mg daily)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: UK‐38,485
Number of subjects: 10
Study: 3776260

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 0
Study: 31532518

Group type: EXPERIMENTAL
Intervention: One-on-one PRISM-P intervention
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Group PRISM-P intervention
Number of subjects: 94

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 94
Study: 28027333

Group type: EXPERIMENTAL
Intervention: Quarterly updated personalized antibiotic prescription feedback over 2 years (n=1450)
Number of subjects: 2900

Group type: COMPARATOR
Intervention: Usual care (n=1450)
Number of subjects: 2900
Study: 25893955

Group type: EXPERIMENTAL
Intervention: Combined inhibition of nitric oxide (NO) and prostaglandin (PG) synthesis (l-NMMA + ketorolac)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Combined KIR channel and Na(+) /K(+) -ATPase inhibition (l-NMMA + ketorolac + BaCl2 + ouabain)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Combined KIR channel and Na(+) /K(+) -ATPase inhibition
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 17
Study: 22864846

Group type: EXPERIMENTAL
Intervention: TeleStroke network hospitals (intervention)
Number of subjects: 1277

Group type: COMPARATOR
Intervention: Control hospitals
Number of subjects: 1277
Study: 21563505

Group type: EXPERIMENTAL
Intervention: Chinese medicine for 12 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Loxoprofen Sodium Tablet and Leifumite Tablet for 12 weeks
Number of subjects: 80
Study: 19571082

Group type: EXPERIMENTAL
Intervention: Recombinant human bone morphogenetic protein-2 (rhBMP-2) on an absorbable collagen sponge with ceramic granules; total dose of rhBMP-2, 12 mg.
Number of subjects: 46

Group type: COMPARATOR
Intervention: Iliac crest bone graft (control group).
Number of subjects: 46
Study: 16776758

Group type: EXPERIMENTAL
Intervention: Traditional warm vertical compaction technique using Touch'n Heat and Obtura II.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Modified warm vertical compaction technique with apical back-filling.
Number of subjects: 60
Study: 15478678

Group type: EXPERIMENTAL
Intervention: EMG-guided BOTOX injection
Number of subjects: 15

Group type: COMPARATOR
Intervention: Non EMG-guided BOTOX injection
Number of subjects: 15
Study: 11012480

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg o.d. + Levofloxacin 500 mg o.d. + Amoxycillin 1 g b.d. (RLA group)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg o.d. + Levofloxacin 500 mg o.d. + Tinidazole 500 mg b.d. (RLT group)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: RLA group
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: RLT group
Number of subjects: 100
Study: 9330929

Group type: EXPERIMENTAL
Intervention: HCQ with MTX as needed for disease flare (n = 40)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: HCQ 400 mg/day (n = 41)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo with MTX as needed for disease flare (n = 40)
Number of subjects: 121
Study: 8452164

Group type: EXPERIMENTAL
Intervention: Fleroxacin, 400 mg once daily
Number of subjects: 301

Group type: COMPARATOR
Intervention: Norfloxacin, 400 mg twice daily
Number of subjects: 301
Study: 2429466

Group type: EXPERIMENTAL
Intervention: Flecainide (2 X 200 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Prajmalium-bitartrate (4 X 20 mg)
Number of subjects: 20
Study: 30053196

Group type: EXPERIMENTAL
Intervention: 6-week home-based aerobic exercise program (EX)
Number of subjects: 41

Group type: COMPARATOR
Intervention: 6-week self-administered cognitive-behavioral therapy for insomnia (CBT-I)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both interventions (EX and CBT-I)
Number of subjects: 41
Study: 27184020

Group type: EXPERIMENTAL
Intervention: 12-week ultrasound examination
Number of subjects: 30000

Group type: COMPARATOR
Intervention: 18-week ultrasound examination
Number of subjects: 30000
Study: 25041791

Group type: EXPERIMENTAL
Intervention: Cixutumumab (6 mg/kg/week intravenously), Erlotinib (100 mg/day orally), Gemcitabine (1000 mg/m2 intravenously on days 1, 8, and 15 of a 28-day cycle)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Erlotinib plus Gemcitabine (control arm)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Cixutumumab
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control (Erlotinib plus Gemcitabine)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Cixutumumab and Control
Number of subjects: 116
Study: 22327716

Group type: EXPERIMENTAL
Intervention: Intraventricular thrombolysis with rt-PA (Actilyse(®)) 5 mg every 12 h and lateral rotational therapy (RotoRest(®))
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study: 20580767

Group type: EXPERIMENTAL
Intervention: High-viscosity glass-ionomer sealants (Ketac Molar Easymix) without energy supplied
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: High-viscosity glass-ionomer sealants (with energy supplied)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Glass-carbomer sealants
Number of subjects: 89

Group type: COMPARATOR
Intervention: Resin composite sealants
Number of subjects: 89
Study: 18078880

Group type: EXPERIMENTAL
Intervention: Early unrestricted weight bearing combined with intensive physiotherapy
Number of subjects: 42

Group type: COMPARATOR
Intervention: Partial weight bearing combined with self-training
Number of subjects: 42
Study: 16245505

Group type: EXPERIMENTAL
Intervention: ThromboCheck device monitoring
Number of subjects: 291

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 291
Study: 12125943

Group type: EXPERIMENTAL
Intervention: Combination ointment (calcipotriol/betamethasone dipropionate)
Number of subjects: 1106

Group type: COMPARATOR
Intervention: Betamethasone dipropionate ointment (Diprosone)
Number of subjects: 1106

Group type: COMPARATOR
Intervention: Calcipotriol ointment (Daivonex)
Number of subjects: 1106

Group type: COMPARATOR
Intervention: Combination ointment vs Betamethasone
Number of subjects: 1106

Group type: COMPARATOR
Intervention: Combination ointment vs Calcipotriol
Number of subjects: 1106

Group type: EXPERIMENTAL
Intervention: Combination ointment
Number of subjects: 1106

Group type: COMPARATOR
Intervention: Betamethasone
Number of subjects: 1106

Group type: COMPARATOR
Intervention: Calcipotriol
Number of subjects: 1106
Study: 10594518

Group type: EXPERIMENTAL
Intervention: Continuous GHRH(1-29)NH2 (60 ng/kg/min, subcutaneous infusion, 24 h)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intermittent SS(1-14) withdrawal (20 microg/m2/hour, intravenous infusion, 3 h on/1 h off, 2-3 cycles over 8-12 h)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combining continuous GHRH with intermittent SS
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Continuous GHRH
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combining intermittent SS with continuous GHRH
Number of subjects: 12

Group type: COMPARATOR
Intervention: Spontaneous GH release in irradiated subjects
Number of subjects: 12
Study: 7786264

Group type: EXPERIMENTAL
Intervention: Ansell Gammex gloves
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baxter Triflex gloves
Number of subjects: 0
Study: 2072886

Group type: EXPERIMENTAL
Intervention: Daily oral supplementation with folic acid before conception and during early pregnancy
Number of subjects: 0
Study: 6864702

Group type: EXPERIMENTAL
Intervention: Atropine combined with methohexitone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate combined with methohexitone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atropine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glycopyrrolate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atropine and Glycopyrrolate
Number of subjects: 0
Study: 30950711

Group type: EXPERIMENTAL
Intervention: Rezum® System thermal therapy
Number of subjects: 188

Group type: COMPARATOR
Intervention: Control (sham rigid cystoscopy)
Number of subjects: 188
Study: 30041267

Group type: EXPERIMENTAL
Intervention: Surgeons' evaluation of nasal appearance
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Patients' self-assessment of nasal appearance
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Nonmedical raters' evaluation of nasal appearance
Number of subjects: 100
Study: 23328549

Group type: EXPERIMENTAL
Intervention: Afatinib plus best supportive care (BSC)
Number of subjects: 585

Group type: COMPARATOR
Intervention: Placebo plus best supportive care (BSC)
Number of subjects: 585
Study: 21886293

Group type: EXPERIMENTAL
Intervention: Healthy Foods Hawai'i (HFH) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 19474141

Group type: EXPERIMENTAL
Intervention: Soy protein (18 g) + isoflavone tablets (105 mg isoflavone aglycone equivalents)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Soy protein + placebo tablets
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Control protein + isoflavone tablets
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control protein + placebo tablets
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Total dietary protein (per kg)
Number of subjects: 131
Study: 17556683

Group type: EXPERIMENTAL
Intervention: Unrandomized SSOB
Number of subjects: 16

Group type: COMPARATOR
Intervention: Randomized SSOB
Number of subjects: 16
Study: 15551252

Group type: EXPERIMENTAL
Intervention: Levofloxacin-based regimen (pantoprazole 40 mg, amoxicillin 1 g, levofloxacin 250 mg, all twice daily for 10 days)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Quadruple therapy (omeprazole 20 mg twice daily for the first week, then omeprazole 20 mg twice daily, tetracycline 250 mg 4 times daily, metronidazole 500 mg twice daily, and bismuth subcitrate 240 mg twice daily for the second week)
Number of subjects: 90
Study: 11721144

Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 729

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 729
Study: 9164809

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 994

Group type: COMPARATOR
Intervention: Conventional anterior surgery
Number of subjects: 994
Study: 7711420

Group type: EXPERIMENTAL
Intervention: MFP‐Ca (13.2 mg fluoride) twice a day
Number of subjects: 20

Group type: COMPARATOR
Intervention: NaF (11.3 mg fluoride) twice a day
Number of subjects: 20
Study: 3117898

Group type: EXPERIMENTAL
Intervention: IVIgG pH 4.25
Number of subjects: 39

Group type: COMPARATOR
Intervention: IVIgG pH 6.8
Number of subjects: 39
Study: 29850873

Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 65
Study: 27132405

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Letrozole
Number of subjects: 0